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Abstract — The researchers involved in the Trans2Care project at the Department 
of Medical and Biological Sciences of the University of Udine investigate the 
biological properties of the antimicrobial peptides (AMPs) of the immune system 
and their therapeutic potential for human and veterinary application. In addition 
to potent and broad-spectrum antimicrobial activities, some AMPs display 
anti-inflammatory and immunomodulatory effects and hold promise as novel 
antiinfective agents combining antibiotic and immunostimulating properties. 
A detailed knowledge of their physicochemical, biological and pharmacological 
properties and of their impact on clinical settings is an important prerequisite 
to this end. The Trans2Care project offers an invaluable opportunity to share 
knowledge, technical expertise and laboratory facilities to achieve a better 
understanding of the biological features and therapeutic potential of AMPs.
Index Terms — antimicrobial peptides, anti-infective drugs, antimicrobial 
activity, cytokine release, immunomodulatory activity
———————————————————
1 UNIVERSITy OF UDINE
The University of Udine is a public institution founded in 1978 as part of the reconstruction plan of Friuli after the earthquake in 1976. It is devoted to higher 
education, research and technology transfer. The University is organized into 10 
faculties and 14 research departments with approx. 16000 enrolled students (a. y. 
2009-2010). The University is actively involved in student and staff exchange projects 
with universities within EU and other non-EU countries and participates in many 
national and international research projects. 
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2 WORKING UNIT 
The Udine working unit includes researchers interested in the characterization and development of plant-based models of drug transport (Department of Agricultural 
and Environmental Sciences), and others involved in the study of antimicrobial 
peptides (AMPs) as templates for the development of novel anti-infective drugs 
(Department of Medical and Biological Sciences).
3  ACTIVITIES AND ROLES IN TRANS2CARE PROjECT 
3.1 Antimicrobial peptides (AMPs) 
AMPs are small, evolutionarily conserved protein components of the innate immune system involved in first-line host defence against infection [1,2]. In mammals, 
two distinct families of such peptides, the defensins [3] and the cathelicidins [4], have 
been detected on epithelial surfaces and in circulating phagocytes. These peptides 
are either constitutively expressed or readily inducible upon infection, inflammation 
or injury [5]. AMPs are quite diverse by length, sequence and secondary structure. 
Common features of these peptides are a small size (12-50 amino acid residues), a 
net positive charge and an amphipathic character [1]. These features enable AMPs 
to interact with negatively-charged microbial membranes and affect the membrane 
integrity, leading to microbial killing [1,5]. Besides exerting direct antimicrobial 
activities, several AMPs have shown the ability to interact with host cells and influence 
cellular processes relevant to inflammation and immunity such as chemotaxis and 
cytokine and chemokine release, and to promote angiogenesis and wound healing 
[2,5].
Fig. 1. Molecular diversity of mammalian AMPs.
3.2 AMPs as templates for the development of novel antiinfective drugs 
Various AMPs have received attention as candidates for the development of novel anti-infective drugs [2,6] to be used in human and veterinary medicine. They 
show several attractive properties in this regard, including i) a potent antimicrobial 
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activity against a wide range of Gram-negative and-positive bacteria and fungi, also 
including multi-drug resistant clinical isolates [6,7]; ii) in vitro antimicrobial efficacy 
in the submicromolar range [6]; iii) low propensity to select resistant mutants 
[5,6]; iv) ability to neutralize proinflammatory microbial components such as the 
lipopolysaccharide and lipotheicoic acid [6,8]; v) ability to modulate host cell functions 
[2,5,7]. Our increasing awareness of the multiple activities of AMPs has encouraged 
studies aimed to evaluate the impact of these molecules on pathophysiological 
processes taking place at specific clinical settings, to define their anti-infective role 
and achieve a safe clinical application.
3.3 Ongoing research activities 
The AMPs under study in our group are examined for i) antimicrobial activity against clinical isolates from epithelial infections; ii) immunomodulatory potential; iii) cell 
proliferation or cytotoxicity-inducing effects. 
i) We are currently investigating the activities of selected AMPs against clinical 
isolates of Candida albicans from human vaginal infections and opportunistic yeast 
pathogens from other sources. The antifungal activity is determined as the minimum 
inhibitory and the minimum fungicidal concentration (MIC and MFC), according to 
the CLSI guidelines. The efficacy of AMPs is also examined using medically relevant 
fungal biofilms, implicated in increased fungal pathogenesis and resistance to drugs 
[9], and adhesion to biotic and abiotic surfaces [10]. Yeast viability is assessed by 
optical density, enumeration of colony forming units (CFU) and XTT tetrazolium salt-
based assay. The effect of AMPs on yeast membrane integrity is quantified by flow 
cytometric and spectrofluorimetric analysis of the cellular uptake of the fluorescent 
dye propidium iodide (PI).
ii) The ability of AMPs to induce cytokine and chemokine gene expression in epithelial 
and macrophagic cells is assessed by qPCR and ELISA. 
iii) Cell proliferation is assayed by a tetrazolium salt-based colorimetric assay. The 
cell membrane integrity is assessed by measuring the cellular uptake of PI and the 
extracellular release of the cytoplasmic enzyme lactate dehydrogenase. Apoptotic 
effects are evaluated by flow cytometry using the annexin V/PI assay.
4 CONCLUSION
A detailed knowledge of their physicochemical, biological and pharmacological properties is a basic prerequisite for translating native peptide molecules into 
innovative products for prevention of infectious/inflammatory diseases. The 
Trans2Care project offers an opportunity to share knowledge, technical expertise 
and laboratory facilities, that can be invaluable to increase our understanding of the 
biological features and therapeutic potential of AMPs. Critically important in this 
regard is the collaboration with Trans2Care partners involved in clinical activities, to 
set up experimental models of infection and inflammation and evaluate the role and 
efficacy of AMPs in specific clinical settings. 
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